Study: NCT02055547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 35μg
Description: Single dose 35μg subcutaneous (SC) injection in a treatment period (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 100μg
Description: Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 100μg
Description: Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 100μg
Description: Single dose 100μg SC injection in a treatment period (Part 1, Panel A) and (Part 2, Panel D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 125μg
Description: Single dose 125μg SC injection in a treatment period (Part 2, Panel E) and (Part 3, Panel H)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 150μg
Description: Single dose 150μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 150μg
Description: Single dose 150μg SC injection in a treatment period (Part 1, Panel B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521 150μg
Description: Single dose 150μg SC injection in a treatment period (Part 1, Panel B)